RegulatoryCNBC-TV18
Aurobindo Pharma shares extend losses after USFDA OAI
Negative-63
GreyOak summary
Aurobindo Pharma shares declined by 3% following the USFDA's classification of an inspection of its subsidiary Lannett Company's facility as Official Action Indicated.
What it affects
- Aurobindo PharmaAUROPHARMANegative -63
Shares fell 3% after USFDA OAI classification.Rolling sentiment Negative -25
Source
Read the original at CNBC-TV18More Aurobindo Pharma news
- USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'Economic Times · Regulatory ·
- Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDAEconomic Times · Regulatory ·
- Aurobindo Pharma snaps 12-day winning streak after USFDA update on subsidiary's API unitCNBC-TV18 · Regulatory ·
- Helios Mid Cap Fund adds Aurobindo Pharma, increases stake in PaytmEconomic Times · Company update ·